• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    9/20/23 5:31:33 PM ET
    $ALZN
    $AVGR
    $BJDX
    $CATX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ALZN alert in real time by email

    Gainers

    • Inventiva (NASDAQ:IVA) stock increased by 11.2% to $4.19 during Wednesday's after-market session. The company's market cap stands at $176.1 million.
    • Bluejay Diagnostics (NASDAQ:BJDX) shares increased by 8.84% to $5.17. Bluejay Diagnostics's trading volume hit 5.4 million shares by close, accounting for 921.8% of its average volume over the last 100 days. The company's market cap stands at $6.4 million.
    • Xilio Therapeutics (NASDAQ:XLO) shares rose 8.4% to $2.45. The market value of their outstanding shares is at $67.4 million.
    • Marinus Pharma (NASDAQ:MRNS) shares increased by 7.71% to $7.75. The company's market cap stands at $392.2 million.
    • Dare Bioscience (NASDAQ:DARE) stock moved upwards by 7.49% to $0.49. The company's market cap stands at $48.0 million.
    • Alzamend Neuro (NASDAQ:ALZN) shares increased by 7.26% to $0.25. The market value of their outstanding shares is at $23.9 million.

    Losers

    • Great Elm Group (NASDAQ:GEG) stock decreased by 14.7% to $1.86 during Wednesday's after-market session. The company's market cap stands at $56.9 million. The company's, Q4 earnings came out today.
    • 4D Molecular Therapeutics (NASDAQ:FDMT) stock fell 6.9% to $13.5. The company's market cap stands at $567.7 million.
    • Perspective Therapeutics (AMEX:CATX) stock fell 6.6% to $0.28. The company's market cap stands at $78.6 million.
    • Avinger (NASDAQ:AVGR) shares decreased by 6.46% to $12.9. Avinger's trading volume hit 2.3 million shares by close, accounting for 183.4% of its average volume over the last 100 days. The company's market cap stands at $8.0 million.
    • Soligenix (NASDAQ:SNGX) shares decreased by 6.27% to $0.48. The company's market cap stands at $4.7 million.
    • Oragenics (AMEX:OGEN) stock decreased by 6.01% to $2.82. The market value of their outstanding shares is at $7.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALZN
    $AVGR
    $BJDX
    $CATX

    CompanyDatePrice TargetRatingAnalyst
    Inventiva S.A.
    $IVA
    3/19/2026$13.00Buy
    Truist
    Perspective Therapeutics Inc.
    $CATX
    2/19/2026$16.00Overweight
    Piper Sandler
    Inventiva S.A.
    $IVA
    1/28/2026$18.00Overweight
    Barclays
    4D Molecular Therapeutics Inc.
    $FDMT
    1/28/2026$33.00Overweight
    Barclays
    Inventiva S.A.
    $IVA
    1/12/2026$12.00Outperform
    Leerink Partners
    Inventiva S.A.
    $IVA
    1/7/2026$12.00Buy
    UBS
    Perspective Therapeutics Inc.
    $CATX
    11/24/2025$12.00Buy
    Truist
    4D Molecular Therapeutics Inc.
    $FDMT
    11/7/2025Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ALZN
    $AVGR
    $BJDX
    $CATX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Hunt Jonathan Robert bought $22,295 worth of shares (11,000 units at $2.03), increasing direct ownership by 23% to 59,800 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/17/25 8:01:56 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Director Williamson Robert F Iii bought $19,946 worth of shares (9,498 units at $2.10) (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/14/25 8:00:03 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    CHAIRMAN, CEO AND PRESIDENT Schaber Christopher J bought $20,000 worth of shares (15,132 units at $1.32), increasing direct ownership by 3,993% to 15,511 units (SEC Form 4)

    4 - SOLIGENIX, INC. (0000812796) (Issuer)

    10/3/25 1:18:09 PM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $AVGR
    $BJDX
    $CATX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2026, the company granted non-qualified stock options to purchase 3,257 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $8.48 per share, which is equal to the closing price of the company's common stock on April 1, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on

    4/3/26 4:30:00 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

    HyBryte™ demonstrates more rapid and robust treatment response compared toValchlor® during 12-week treatment coursePRINCETON, N.J., April 2, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the positive results of its comparability study evaluating HyBryte™ (synthetic hypericin) versus Valchlor® (mechlorethamine) for the treatment of cutaneous T-cell lymphoma (CTCL) have been published in Oncology and Therapy. 

    4/2/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perspective Therapeutics to Participate in Upcoming Investor Conferences

    SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: 25th Annual Needham Virtual Healthcare Conference – Presentation & Fireside ChatDate: Tuesday, April 14, 2026Time: 9:30-10:10 a.m. ET Location: Virtual Piper Sandler Spring Biopharma Symposium – 1x1s onlyDate: Thursday, April 16, 2026Location: Boston, MA About Perspective Therapeutics, Inc.

    4/2/26 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $ALZN
    $AVGR
    $BJDX
    $CATX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Shannon James Samuel

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    3/30/26 5:29:01 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Simms Christopher Paul

    4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)

    3/27/26 4:30:02 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Kirn David

    4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)

    3/27/26 4:30:07 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALZN
    $AVGR
    $BJDX
    $CATX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Inventiva with a new price target

    Truist initiated coverage of Inventiva with a rating of Buy and set a new price target of $13.00

    3/19/26 8:26:25 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Perspective Therapeutics with a new price target

    Piper Sandler initiated coverage of Perspective Therapeutics with a rating of Overweight and set a new price target of $16.00

    2/19/26 7:52:02 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Inventiva with a new price target

    Barclays initiated coverage of Inventiva with a rating of Overweight and set a new price target of $18.00

    1/28/26 7:17:30 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $AVGR
    $BJDX
    $CATX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XACIATO issued to DARE BIOSCIENCE INC

    Submission status for DARE BIOSCIENCE INC's drug XACIATO (ORIG-1) with active ingredient CLINDAMYCIN PHOSPHATE has changed to 'Approval' on 12/07/2021. Application Category: NDA, Application Number: 215650, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/7/21 12:35:25 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $AVGR
    $BJDX
    $CATX
    SEC Filings

    View All

    SEC Form EFFECT filed by Soligenix Inc.

    EFFECT - SOLIGENIX, INC. (0000812796) (Filer)

    4/3/26 12:15:07 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Soligenix Inc.

    EFFECT - SOLIGENIX, INC. (0000812796) (Filer)

    4/3/26 12:15:04 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Soligenix Inc.

    EFFECT - SOLIGENIX, INC. (0000812796) (Filer)

    4/3/26 12:15:15 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $AVGR
    $BJDX
    $CATX
    Financials

    Live finance-specific insights

    View All

    Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

    Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today reported financial results for the year ended December 31, 2025, and provided a business update. "We are not a company that is just getting into women's health. We are a women's health biotech company – and we believe 2026 is the year investors wi

    3/26/26 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results

    Daix (France), New York (United States), March 23, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that it will release its 2025 full-year financial results on Monday, March 30, 2026, after market close in the United States. Inventiva's management will hold a conference call in English, followed by a Q&A session, on Tuesday, March 31, 2026, at 8:00 am (New York), 2:00 pm (Paris). Participants wishing to join the conference call by phone and ask questions must register in advance here. Upon regis

    3/23/26 5:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026

    SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 26, 2026, to review its financial results for the year ended December 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 1717423. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website

    3/20/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $AVGR
    $BJDX
    $CATX
    Leadership Updates

    Live Leadership Updates

    View All

    Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results

    XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Plan to present new preclinical data at AACR for potential first-in-class masked T cell engager program targeting CLDN18.2 Extended cash runway through the end of 2027 WALTHAM, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced pipeline progress and busin

    3/23/26 7:30:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

    Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa

    11/20/25 8:00:00 PM ET
    $AURA
    $FDMT
    $NBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    4DMT Appoints Kristian Humer as Chief Financial Officer

    EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the appointment of Kristian Humer as Chief Financial Officer. Mr. Humer will lead the Company's financial strategy and operations, including responsibility for financial planning, capital allocation, corporate development and supporting strategic initiatives. Mr. Humer is an accomplished finance executive and biotechnology leader with more than two decades of experience

    11/17/25 6:00:00 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALZN
    $AVGR
    $BJDX
    $CATX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Great Elm Group Inc.

    SC 13D/A - Great Elm Group, Inc. (0001831096) (Filed by)

    12/13/24 4:41:14 PM ET
    $GEG
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by Great Elm Group Inc.

    SC 13D/A - Great Elm Group, Inc. (0001831096) (Subject)

    12/10/24 7:01:07 PM ET
    $GEG
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by Great Elm Group Inc.

    SC 13D/A - Great Elm Group, Inc. (0001831096) (Subject)

    12/3/24 8:11:57 PM ET
    $GEG
    Computer Software: Prepackaged Software
    Technology